GP
PRTK

GLG Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

GLG Partners’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$3.39M Buy
189,219
+64,801
+52% +$1.35M 0.16% 166
2017
Q3 		$3.12M Buy
+124,418
New +$2.9M 0.17% 153

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

GLG Partners's PRTK Position: Q4 2017 in Review

GLG Partners increased its Paratek Pharmaceuticals, Inc. (PRTK) stake by 52% in Q4 2017, buying an estimated $1.35M and bringing the position to 189,219 shares worth $3.39M. The position accounts for 0.16% of the portfolio, ranked #166.

GLG Partners first reported a position in PRTK in Q3 2017 and has held it in 2 quarters since. 116 funds tracked by Wall St. Rank hold PRTK as of Q4 2017.

  • GLG Partners held 189,219 shares of Paratek Pharmaceuticals, Inc. worth $3.39M as of Q4 2017.
  • GLG Partners bought 64,801 Paratek Pharmaceuticals, Inc. shares in Q4 2017, an estimated $1.35M.
  • Paratek Pharmaceuticals, Inc. made up 0.16% of GLG Partners's portfolio in Q4 2017, its #166 holding.
  • GLG Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2017 and has held it in 2 quarters since.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.